Collectively, our findings suggest that combined administration of Aurora kinase A or PLK1 and WEE1 inhibitors could be a promising strategy to enhance apoptosis in TKI-resistant CML cells. The gene discussed is WEE1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.